In addition, high expression of SIRT6 is associated with poor prognosis in NSCLC patients, and SIRT6 knockdown increases the sensitivity of lung adenocarcinoma cell lines to paclitaxel [55]. Here, SIRT6 is linked to lung adenocarcinoma.